Equities research analysts expect AC Immune SA (NASDAQ:ACIU) to announce sales of $3.57 million for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for AC Immune’s earnings, with estimates ranging from $2.00 million to $5.14 million. AC Immune reported sales of $1.41 million during the same quarter last year, which indicates a positive year over year growth rate of 153.2%. The firm is expected to report its next quarterly earnings results on Thursday, March 19th.
According to Zacks, analysts expect that AC Immune will report full-year sales of $113.32 million for the current financial year, with estimates ranging from $109.96 million to $118.00 million. For the next year, analysts expect that the business will post sales of $31.41 million, with estimates ranging from $30.81 million to $32.00 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow AC Immune.
AC Immune (NASDAQ:ACIU) last issued its quarterly earnings data on Wednesday, November 13th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.17 by $0.08. AC Immune had a return on equity of 19.18% and a net margin of 45.19%. The company had revenue of $33.90 million for the quarter, compared to analyst estimates of $31.50 million.
ACIU has been the topic of several research analyst reports. BidaskClub raised AC Immune from a “buy” rating to a “strong-buy” rating in a report on Friday, January 10th. ValuEngine raised AC Immune from a “hold” rating to a “buy” rating in a report on Friday, January 3rd. Zacks Investment Research raised AC Immune from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a report on Tuesday, January 14th. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective (up from $8.00) on shares of AC Immune in a report on Tuesday, December 10th. Finally, TheStreet raised AC Immune from a “d” rating to a “c” rating in a report on Monday, November 18th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $11.00.
ACIU traded down $0.51 during trading on Friday, hitting $9.20. The company’s stock had a trading volume of 152,100 shares, compared to its average volume of 206,462. The company has a current ratio of 22.08, a quick ratio of 22.09 and a debt-to-equity ratio of 0.01. AC Immune has a twelve month low of $3.25 and a twelve month high of $11.55. The business’s fifty day simple moving average is $8.71 and its 200 day simple moving average is $6.39. The firm has a market capitalization of $621.57 million, a price-to-earnings ratio of 13.14 and a beta of 0.37.
Several large investors have recently modified their holdings of ACIU. Millennium Management LLC boosted its stake in shares of AC Immune by 516.5% in the third quarter. Millennium Management LLC now owns 122,806 shares of the company’s stock worth $607,000 after acquiring an additional 102,887 shares during the last quarter. Citadel Advisors LLC boosted its stake in shares of AC Immune by 34.2% in the second quarter. Citadel Advisors LLC now owns 166,427 shares of the company’s stock worth $924,000 after acquiring an additional 42,414 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of AC Immune by 12.6% in the second quarter. Renaissance Technologies LLC now owns 248,039 shares of the company’s stock worth $1,377,000 after acquiring an additional 27,789 shares during the last quarter. Tower Research Capital LLC TRC acquired a new stake in shares of AC Immune in the third quarter worth approximately $62,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of AC Immune in the second quarter worth approximately $58,000. 27.80% of the stock is currently owned by hedge funds and other institutional investors.
AC Immune Company Profile
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Further Reading: What is the S&P/TSX Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.